Cyclooxygenase-2 and ERBB-2 in Cholangiocarcinoma: Potential Therapeutic Targets

ABSTRACT

Cholangiocarcinoma is a rare but highly malignant primary hepatobiliary cancer with a high rate of mortality. Early diagnosis is difficult and current therapies are ineffective for the advanced disease. Although the molecular pathogenesis of cholangiocarcinoma is still poorly understood, there is increasing evidence to suggest that overexpression of the proto-oncogene-encoded receptor tyrosine kinase ERBB-2 together with upregulation of cyclooxygenase-2 (COX-2) may be an important feature of cholangiocarcinogenesis in both the human and the experimental rodent models. Evidence presented supports a strong positive correlation between ERBB-2 overexpression and cyclooxygenase upregulation in human cholangiocarcinogenesis. Combination drug targeting of ERBB-2 and of COX-2 was also found to act synergistically to suppress anchorage-independent growth and activate caspase-3 in cultured rat cholangiocarcinoma cells overexpressing both proteins. These findings suggest that aberrant expression of ERBB-2 and COX-2 is a common feature of human and rat cholangiocarcinomas and that targeting of both proteins may prove useful as a therapeutic strategy for this lethal cancer.

KEYWORDS

Cholangiocarcinogenesis - ERBB-2 - cyclooxygenase-2 - therapeutic targeting

REFERENCES

• 1 Weber S M, Jarnagin W R, Klimstra D. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes.  J Am Coll Surg . 2001;  193 384-391
• 2 Uenishi T, Hirohashi K, Kubo S. Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma.  World J Surg . 2001;  25 865-869
• 3 Jarnagin W R, Fong Y, DeMatteo R P. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.  Ann Surg . 2001;  234 507-519
• 4 De Groen C P, Gores G J, LaRusso N F, Gunderson L L, Nagorney D M. Biliary tract cancers.  N Engl J Med . 1999;  341 1368-1378
• 5 Sirica A E, Gainey T W, Harrell M B, Caran N. Cholangiocarcinogenesis and biliary adaptation responses in hepatic injury. In: Sirica AE, Longnecker DS, eds. Biliary and Pancreatic Ductal Epithelia-Pathobiology and Pathophysiology New York: Marcel Dekker 1997: 229-290
• 6 Chapman R W. Risk factors for biliary tract carcinogenesis.  Ann Oncol . 1999;  10(Suppl 4) S308-S311
• 7 Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.  Hepatology . 2001;  33 1353-1357
• 8 Suzuki H, Isaji S, Pairojkul C, Uttaravichien T. Comparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan.  J Hepatobiliary Pancreat Surg . 2000;  7 206-211
• 9 Chu K-M, Lo C-M, Liu C-L, Fan S-T. Malignancy associated with hepatolithiasis.  Hepatogastroenterology . 1997;  44 352-357
• 10 Su W-C, Shiesh S-C, Liu H-S, Chen C-Y, Chow N-H, Lin X-Z. Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-β, and PDGF in bile from biliary malignancies and inflammatory disorders.  Dig Dis Sci . 2001;  46 1387-1392
• 11 Chen T-C, Nakanuma Y, Zen Y, Chen M-F. Intraductal papillary neoplasia of the liver associated with hepatolithiasis.  Hepatology . 2001;  34 651-658
• 12 Ponsioen C IJ, Tytgat G NJ. Primary sclerosing cholangitis: a clinical review.  Am J Gastroenterol . 1998;  93 515-523
• 13 Harrison P M. Prevention of bile duct cancer in primary sclerosing cholangitis.  Ann Oncol . 1999;  10(Suppl 4) S208-S211
• 14 Komi N, Tamura T, Miyoshi Y. Histochemical and immunohistochemical studies on development of biliary carcinoma in forty-seven patients with choledochal cysts-special reference to intestinal metaplasia in the biliary duct.  Jpn J Surg . 1985;  15 273-278
• 15 Imazu M, Iwai N, Tokiwa K, Shimotake T, Kimura O, Ono S. Factors of biliary carcinogenesis in choledochal cysts.  Eur J Pediatr Surg . 2001;  11 24-27
• 16 Taylor-Robinson S D, Toledano M B, Arora S. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998.  Gut . 2001;  48 816-820
• 17 Shirabe K, Shimada M, Harimoto N. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities.  Surgery . 2002;  131 S159-S164
• 18 Bathe O F, Pacheco J T, Ossi P B. Management of hilar bile duct carcinoma.  Hepatogastroenterlogy . 2001;  48 1289-1294
• 19 Sirica A E, Lai G-H, Zhang Z. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies.  J Gastroenterol Hepatol . 2001;  16 363-372
• 20 Sirica A E, Endo K, Lai G-H, Demetris A J, Pairojkul C, Terada T. COX-2 and ERBB-2/NEU in human and rat cholangiocarcinomas: potential therapeutic targets.  Hepatology . 2001;  34 191A
• 21 Lohrisch C, Piccart M. An overview of HER2.  Semin Oncol . 2001;  28(Suppl 18) 3-11
• 22 Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.  Crit Rev Clin Lab Sci . 2000;  37 431-502
• 23 Andrechek E R, Muller W J. Tyrosine kinase signaling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer.  Breast Cancer Res . 2000;  2 211-216
• 24 Liu C H, Chang S-H, Narko K. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice.  J Biol Chem . 2001;  276 18563-18569
• 25 Voravud N, Foster C S, Gilbertson J A, Sikora K, Waxman J. Oncogene expression in cholangiocarcinoma and in normal hepatic development.  Hum Pathol . 1989;  20 1163-1168
• 26 Terada T, Ashida K, Endo K. c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma.  Histopathology . 1998;  33 325-331
• 27 Brunt E M, Swanson P E. Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver.  Am J Clin Pathol . 1992;  97(Suppl 1) S53-S61
• 28 Aishima S-I, Taguchi K-I, Sugimachi K. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma.  Histopathology . 2002;  40 269-278
• 29 Ito Y, Takeda T, Sasaki Y. Expression and clinical significance of the erbB family in intrahepatic cholangiocarcinoma.  Pathol Res Pract . 2001;  197 95-100
• 30 Chow N-H, Huang S-M, Chan S-H. Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract.  Anticancer Res . 1995;  15 1055-1060
• 31 Collier J D, Guo K, Mathew J. c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma.  J Hepatol . 1992;  14 377-380
• 32 Press M F, Hung G, Godolphin W, Slamon D J. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.  Cancer Res . 1994;  54 2771-2777
• 33 Chariyalertsak S, Sirikulchayanonta V, Mayer D. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma.  Gut . 2001;  48 80-86
• 34 Hayashi N, Yamamoto H, Hiraoka N. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm.  Hepatology . 2001;  34 638-650
• 35 Endo K, Yoon B I, Pairojkul C, Demetris A J, Sirica A E. ERBB-2 over-expression and cyclooxygenase-2 up-regulation in human cholangiocarcioma and associated risk conditions (in press).  Hepatology. 2002; 
• 36 Koga H, Sakisaka S, Ohishi M. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor differentiation.  Hepatology . 1999;  29 688-696
• 37 Ghosh M, Kawamoto T, Koike N. Cyclooxygenase expression in the gallbladder.  Int J Mol Med . 2000;  6 527-532
• 38 Maronpot R R, Giles H D, Dykes D J, Irwin R D. Furan-induced hepatic cholangiocarcinomas in Fischer 344 rats.  Toxicol Pathol . 1991;  19 561-570
• 39 Elmore L W, Sirica A E. ``Intestinal-type'' of adenocarcinoma preferentially induced in right/caudate liver lobes of rats treated with furan.  Cancer Res . 1993;  53 254-259
• 40 Sirica A E. Biliary proliferation and adaptation in furan-induced rat liver injury and carcinogenesis.  Toxicol Pathol . 1996;  24 90-99
• 41 Sirica A E, Radaeva S, Caran N. NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia.  Am J Pathol . 1997;  151 1685-1694
• 42 Radaeva S, Ferreira-Gonzalez A, Sirica A E. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma.  Hepatology . 1999;  29 1453-1462
• 43 Lai G-H, Sirica A E. Establishment of a novel rat cholangiocarcinoma cell culture model.  Carcinogenesis . 1999;  20 2335-2339
• 44 Shiraishi K, Kusano N, Okita S. Genetic aberrations detected by comparative genomic hybridization in biliary tract cancers.  Oncology . 1999;  57 42-49
• 45 Kiguchi K, Carbajal S, Chan K. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma.  Cancer Res . 2001;  61 6971-6976
• 46 Half E, Tang X M, Gwyn K. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.  Cancer Res . 2002;  62 1676-1681
• 47 Vadlamudi R, Mandal M, Adam L. Regulation of cyclooxygenase-2 pathway by HER2 receptor.  Oncogene . 1999;  18 305-314
• 48 Yoon J-H, Higuchi H, Werneburg N W, Kaufmann S H, Gores G J. Bile acids induce cycloxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line.  Gastroenterology . 2002;  122 905-993
• 49 Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line.  J Gastroenterol Hepatol . 1994;  9 462-467
• 50 Sugawara H, Yasoshima M, Katayanagi K. Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma.  Histopathology . 1998;  33 145-153
• 51 Park J, Tadlock L, Gores G J, Patel T. Inhibition of interleukin-6 mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line.  Hepatology . 1999;  30 1128-1133
• 52 Yokomuro S, Tsuji H, Lunz III G J. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor β1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells.  Hepatology . 2000;  32 26-35
• 53 Qiu Y, Ravi L, Kung H-J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells.  Nature . 1998;  393 83-85
• 54 Jee S-H, Shen S-C, Chiu H-C, Tsai W-L, Kuo M-L. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency.  Oncogene . 2001;  20 198-208
• 55 Hinson R M, Williams J A, Shacter E. Elevated interleukin 6 is induced by prostaglandin E₂ in a murine model of inflammation: Possible role of cyclooxygenase-2.  Proc Natl Acad Sci USA . 1996;  93 4885-4890
• 56 Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia.  Ann Clin Lab Sci . 2000;  30 3-21
• 57 Liu X-H, Kirschenbaum A, Lu M. Prostaglandin E2 stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway.  Biochem Biophys Res Commu . 2002;  290 249-255
• 58 Zhang L, Chang C, Bacus S S, Hung M-C. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.  Cancer Res . 1995;  55 3890-3896
• 59 Zhang L, Lau Y-K, Xia W, Hortobagyi G N, Hung M-C. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.  Clin Cancer Res . 1999;  5 343-353
• 60 Yu D, Hung M-C. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.  Oncogene . 2000;  19 6115-6121
• 61 Arteaga C L, Chinratanalab W, Carter M B. Inhibitors of HER2/neu (erbB-2) signal transduction.  Semin Oncol . 2001;  28(Suppl 18) 30-35
• 62 Slamon D J, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.  N Engl J Med . 2001;  344 783-792
• 63 Steinbach G, Lynch P M, Phillips R KS. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.  N Engl J Med . 2000;  342 1946-1952
• 64 Cruz-Correa M, Hylind L M, Romans K E, Booker S V, Giardiello F M. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.  Gastroenterology . 2002;  122 641-645
• 65 Mann M, Sheng H, Shao J. Targeting Cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.  Gastroenterology . 2001;  120 1713-1719